[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"venous-insufficiency-of-leg\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:venous-insufficiency-of-leg":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,55,81,117,145,165,189],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":35,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100602421","effect-of-photobiomodulation-on-healing-of-venous-leg-ulcers-100602421",false,"NCT07123285","Effect of Photobiomodulation on Healing of Venous Leg Ulcers","Effect of Photobiomodulation on the Healing of Venous Ulcers in the Lower Limbs","Inclusion Criteria:\n\n* Patients of both sexes;\n* Individuals with venous ulcers in the lower limbs for at least three weeks that have not healed;\n* Age between 18 and 85 years;\n* Residents of Lençóis Paulista or nearby regions.\n\nExclusion Criteria:\n\n* Patients with ulcers of non-venous etiology;\n* Pregnant women;\n* Presence of severe arterial disease in the lower limbs.","ALL","18 Years","85 Years",{"count":20,"type":21},96,"ESTIMATED","INTERVENTIONAL",[24],"NA","This randomized, controlled, double-blind clinical trial will evaluate the efficacy of photobiomodulation (PBM) combined with compression therapy in the healing of venous ulcers (VUs) in the lower limbs. A total of 96 participants will be allocated into two groups: Experimental Group (PBM + compression) and Control Group (sham PBM + compression). Treatments will be administered twice weekly for 16 weeks (32 sessions). The primary outcome will be complete wound healing. Secondary outcomes include changes in ulcer area and volume, pain (VAS), quality of life (SF-36), clinical severity (VCSS), wound quality (Bates-Jensen Scale), infrared thermography, and treatment costs. Data will be analyzed using ANOVA or Kruskal-Wallis, chi-square or Fisher's exact test, and Kaplan-Meier survival analysis, with a significance level of p \\\u003C 0.05.",[27,28,29,30,31,32,33,34],"Venous Disease","Venous Insufficiency (Chronic)(Peripheral)","Venous Insufficiency of Leg","Venous Leg Ulcer (VLU)","Venous Leg Ulcer","Venous Hypertension Ulcers","Varicose Ulcers","Varicose Ulcer of Lower Limb",[36,37,38,39,40,41],"venous ulcers","varicose ulcers","photobiomodulation","lasers","phototherapy","venous leg ulcer","NOT_YET_RECRUITING","2026-04-27",{"date":45,"type":46},"2026-04-29","ACTUAL",{"date":48,"type":21},"2026-05",{"date":50,"type":21},"2027-07",{"name":52,"class":53},"University of Nove de Julho","OTHER",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":22,"phases":64,"briefSummary":65,"conditions":66,"keywords":67,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":77,"leadSponsor":79,"locationsCount":54},"100620830","therapeutic-efficacy-of-the-phlebology-oriented-thermal-cure-at-the-saint-eloy-thermal-center-in-the-treatment-of-symptoms-of-severe-chronic-venous-insufficiency-100620830","NCT07362719","Therapeutic Efficacy of the Phlebology-oriented Thermal Cure at the Saint-Eloy Thermal Center in the Treatment of Symptoms of Severe Chronic Venous Insufficiency","AMNEVILLE-PHL","Inclusion Criteria:\n\n* Adult male or female (≥ 18 years of age).\n* Patients with severe chronic venous insufficiency of the lower limbs (C4a,b,c - C5 according to the CEAP (Clinical manifestations, Etiology, Anatomic distibution, Pathophysiology) classification (2020 revision) for at least one of the legs) confirmed by venous Doppler ultrasound of the lower limbs.\n* Patients with an indication for a thermal cure exclusively focused on phlebology.\n* Patients available to participate in a 3-week consecutive thermal cure at the Saint-Eloy Thermal Center, followed by 6 months of clinical follow-up, in accordance with the protocol schedule.\n* Patients available to attend the visits scheduled in the protocol and able to complete the data collection documents.\n* For women of childbearing age: patient using effective contraception.\n* Patient affiliated with a health insurance plan or beneficiary (Art. L.1121-8-1, French Public Health Code).\n* Patient who has given their informed consent in writing regarding their participation in the protocol.\n\nExclusion Criteria:\n\n* Patients with a contraindication to thermal cure.\n* Patients who have participated in thermal cure (regardless of type) within the last 9 months.\n* Patients who have had an ulcer on their lower limbs that has healed within the last 3 months.\n* Patients without venous trophic disorders of the lower limbs, and in particular patients with isolated class C3 chronic venous insufficiency or less in both lower limbs.\n* Patients with an open ulcer on a lower limb (class C6).\n* Patients for whom interventional venous treatment is due to begin within the next 6 months.\n* Patients scheduled to undergo orthopedic surgery on the lower limbs within the next 6 months.\n* Patients who are unable to walk.\n* Patients with a known allergy to sulfur.\n* Patients with any medically significant findings or significant history that may impact safety, interpretation of results, and\u002For subject participation in the study at 6 months, in the investigator's opinion.\n* Patients simultaneously participating in another clinical trial or who have participated in another clinical trial for which the exclusion period has not ended.\n* Vulnerable persons (Art. L.1121-5 to 8, and L1122-1-2, French Public Health Code).",{"count":63,"type":21},84,[24],"Chronic venous insufficiency (CVI) is a common progressive vascular disease that affects nearly one-third of the French population. Despite considerable advances in the treatment of chronic venous insufficiency, this condition remains a burden for patients and national healthcare systems.\n\nBalneotherapy-which includes thermal cures-is part of the therapeutic arsenal used in the treatment of chronic venous insufficiency. It is a relatively effective alternative with a relatively low cost compared to drug or surgical treatments. Phlebology is a thermal treatment orientation recognized by the French social security system.\n\nThe Saint-Eloy Thermal Center is listed among the thermal stations approved by the French Ministry of Health. It currently uses thermal water from Amnéville-les-Thermes to treat rheumatological and respiratory conditions, and wants to expand its range of orientations by adding phlebology. The AMNEVILLE-PHL study therefore aims to evaluate the efficacy and safety of the Saint-Eloy thermal cure for phlebology in patients suffering from severe chronic venous insufficiency.",[29],[68,69,70,71,29],"Severe chronic venous insufficiency","Thermal cure","Phlebology","Balneology","RECRUITING","2026-02-27",{"date":75,"type":46},"2026-03-02",{"date":73,"type":46},{"date":78,"type":21},"2027-05",{"name":80,"class":53},"Société d'Exploitation des Thermes d'Amnéville",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":91,"briefSummary":93,"conditions":94,"keywords":101,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":116},"100570426","phase-3-tissue-repair-gel-in-venous-leg-ulcers-us-100570426","NCT06707090","Tissue Repair Gel in Venous Leg Ulcers (US)","A Phase 3 Randomized, Parallel Group, Double-Blind Study to Evaluate the Efficacy, Tolerability, and Safety of TR987® 0.1% Gel Versus Standard of Care in the Treatment of Chronic Venous Insufficiency Leg Ulcers (VLU)","TRIVIA","Inclusion Criteria:\n\n* Adults 18 years and older\n* Venous insufficiency has been clinically diagnosed clinically and medically confirmed.\n* Females who are neither pregnant nor breastfeeding and if of child-bearing potential are on an acceptable method of birth control.\n* The Venous Ulcer should be between 2 cm2 and 12 cm2 at randomization.\n* Target ulcer age must be ≥ 4 weeks at Screening.\n* Participants must have adequate arterial flow as confirmed by ABI\u002FTBI, TB, SPP, TCPo2, or Duplex Doppler.\n* Body mass index (BMI) ≤ 50 kg\u002Fm2.\n* HbA1C ≤12%.\n\nExclusion Criteria:\n\n* Target ulcer has been treated with prohibited medications or therapies.\n* History of radiation at the target ulcer site.\n* Target ulcer decreases in area by 30% or more during screening period.\n* History of osteomyelitis at the target ulcer within 6 months of screening.\n* Participants considered nutritionally deficient.",{"count":90,"type":21},312,[92],"PHASE3","The goal of this clinical trial is to learn if TR987 0.1% gel + Standard of Care works better than Standard of Care alone to treat Venous Leg Ulcers (VLUs). It will also provide additional information about the safety of drug TR987 0.1% gel.",[31,95,96,97,98,99,29,100],"Venous Ulcer","Venous Stasis Ulcer","Venous Stasis","Wound Heal","Wounds","Non-healing Wound",[102,103,104,105,106],"Tissue Repair","Glucoprime","TR Therapeutics","Debridement","VLU","2026-02-09",{"date":109,"type":46},"2026-02-12",{"date":111,"type":46},"2025-01-28",{"date":113,"type":21},"2028-02",{"name":104,"class":115},"INDUSTRY",33,{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":124,"enrollmentInfo":125,"targetDuration":4,"studyType":22,"phases":127,"briefSummary":128,"conditions":129,"keywords":132,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":54},"100596501","clinical-outcomes-safety-and-cost-effectiveness-analysis-of-two-catheters-xianrui-da-and-medtronic-in-radiofrequency-ablation-for-varicose-veins-100596501","NCT07046286","Clinical Outcomes, Safety, and Cost-Effectiveness Analysis of Two Catheters (Xianrui Da and Medtronic) in Radiofrequency Ablation for Varicose Veins","Clinical Outcomes, Safety, and Cost-Effectiveness Analysis of Two Catheters (Xianrui and Medtronic) in Radiofrequency Ablation for Varicose Veins","Inclusion Criteria:\n\n1. Age between 18 and 80 years old.\n2. Clinically diagnosed with primary lower extremity varicose veins, with CEAP grade C2 - C5, and requiring treatment of the great saphenous vein segment.\n3. Doppler ultrasound confirms that the reflux time of the saphenofemoral vein valve is \\> 1.0 second.\n4. Doppler ultrasound confirms that the diameter of the great saphenous vein in the supine position is \\> 3mm and \\\u003C 12mm.\n5. Only one limb of each patient is included in the study.\n6. The patient signs the informed consent form and is willing to cooperate with the examinations and follow - ups specified in the protocol.\n\nExclusion Criteria:\n\n1. Thrombosis in the great saphenous vein, or combined with deep vein thrombosis, or a history of deep vein thrombosis or pulmonary embolism.\n2. Recurrent varicose veins after previous treatment.\n3. Severe tortuosity of the great saphenous vein, with the expectation that the catheter cannot pass through.\n4. Severe lower extremity ischemia (CLI).\n5. Known allergy to drugs or device materials involved in the study.\n6. History of cardiac pacemaker or defibrillator implantation.\n7. Pregnant or breastfeeding women.\n8. Currently participating in other drug or device studies.\n9. Deemed unsuitable for endovenous treatment by the researcher.","80 Years",{"count":126,"type":21},200,[24],"This study aims to systematically compare the clinical efficacy (venous closure rate and symptom relief rate), safety (perioperative and postoperative complications), and cost-effectiveness (direct medical costs) of domestic Xianruida radiofrequency catheter and imported Medtronic catheter in endovenous radiofrequency ablation for varicose veins through a single-center, prospective, non-inferiority randomized controlled trial.",[130,29,131],"Varicose Veins of Lower Limb","Vascular Disease，Peripheral",[133,134,135],"varicose veins of the great saphenous veins","radiofrequency ablation","catheters","2025-06-29",{"date":138,"type":46},"2025-07-01",{"date":140,"type":21},"2025-08-01",{"date":142,"type":21},"2026-10-01",{"name":144,"class":53},"Chengdu University of Traditional Chinese Medicine",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":86,"acronym":87,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":22,"phases":152,"briefSummary":93,"conditions":153,"keywords":155,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":164},"100570427","phase-3-tissue-repair-gel-in-venous-leg-ulcers-in-auus-100570427","NCT06707103","Tissue Repair Gel in Venous Leg Ulcers in AU\u002FUS","Inclusion Criteria:\n\n* Adults 18 years and older\n* Venous insufficiency has been clinically diagnosed clinically and medically confirmed.\n* Females who are neither pregnant nor breastfeeding and if of child-bearing potential are on an acceptable method of birth control.\n* The Venous Ulcer should be between 2 cm2 and 12 cm2 at randomization.\n* Target ulcer age must be ≥ 4 weeks at Screening.\n* Participants must have adequate arterial flow as confirmed by ABI\u002FTBI, TB, SPP, TCPo2, or Duplex Doppler.\n* Body mass index (BMI) ≤ 50 kg\u002Fm2.\n* HbA1C ≤12%.\n\nExclusion Criteria:\n\n* Target ulcer has been treated with prohibited medications or therapies.\n* History of radiation at the target ulcer site.\n* Target ulcer decreases in area by 30% or more during screening period.\n* History of osteomyelitis at the target ulcer within 6 months of screening.\n* History of cancer in the preceding 5 years (except as noted in the protocol).\n* Participants considered nutritionally deficient.",{"count":90,"type":21},[92],[31,95,96,97,98,154,29,100],"Wound",[102,103,104,105,106],"2025-03-27",{"date":158,"type":46},"2025-04-02",{"date":160,"type":21},"2025-04",{"date":162,"type":21},"2027-02",{"name":104,"class":115},12,{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":172,"enrollmentInfo":173,"targetDuration":4,"studyType":22,"phases":175,"briefSummary":176,"conditions":177,"keywords":178,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":54},"100570736","comparative-analysis-of-radiofrequency-ablation-and-microwave-ablation-procedures-for-the-treatment-of-small-saphenous-varicose-veins-100570736","NCT06711120","Comparative Analysis of Radiofrequency Ablation and Microwave Ablation Procedures for the Treatment of Small Saphenous Varicose Veins","Randomized Controlled Study of Radio Frequency and Microwave of the Small Saphenous Vein","Inclusion Criteria:\n\n* Age ≥18 years and ≤90 years;\n* Clinical diagnosis of primary varicose veins of the lower extremities, CEAP clinical classification C2-C6, requiring treatment of the great and\u002For small saphenous vein segments, and at least 1 of the clinical symptoms of swelling, pain, burning sensation, heaviness, easy fatigue, itchy skin, and night cramps;\n* Valve insufficiency of the great saphenous vein, small saphenous vein, or transport vein;\n* Doppler ultrasound confirmation of a saphenous vein diameter greater than 3 mm and less than 12 mm in the standing position;\n* Only one limb per patient was selected for inclusion in the study;\n* Patients signed an informed consent form and were willing to co-operate in completing the protocol-specified investigations and follow-up visits.\n\nExclusion Criteria:\n\n* Thrombosis of the great saphenous or small saphenous vein, or combined deep vein thrombosis, or previous history of deep vein thrombosis or pulmonary embolism.\n* Recurrent varicose veins after previous treatment.\n* Severe distortion of the great saphenous vein with anticipated catheter failure.\n* Severe lower limb ischaemia (CLI) (ABPI \\\u003C0.8).\n* Known allergy to medications and device materials involved in the study.\n* Pre-existing implanted pacemaker, defibrillator, currently on regular anticoagulation therapy (e.g., warfarin, heparin).\n* Women who are pregnant or breastfeeding.\n* Unable or unwilling to complete the questionnaire.\n* Participating in a study of another drug or device.\n* Life expectancy \\\u003C1 year.\n* Those undergoing treatment for skin malignancies other than non-melanoma.\n* Daily use of narcotic drugs or non-steroidal anti-inflammatory drugs to control pain due to venous disease.\n* In the judgement of the investigator, endovenous therapy is not appropriate.","90 Years",{"count":174,"type":21},150,[24],"Objective: To investigate the clinical efficacy of ultrasound-guided radiofrequency ablation and microwave ablation in the treatment of primary saphenous varicose veins.",[130,29,131],[179,134,180],"varicose veins of the small saphenous veins","microwave ablation","2024-11-28",{"date":183,"type":46},"2024-12-02",{"date":185,"type":21},"2024-12-01",{"date":187,"type":21},"2025-12-01",{"name":144,"class":53},{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":172,"enrollmentInfo":195,"targetDuration":197,"studyType":198,"phases":4,"briefSummary":199,"conditions":200,"keywords":201,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":210,"leadSponsor":211,"locationsCount":54},"100569361","observation-of-pain-during-the-treatment-of-great-saphenous-vein-using-microwave-ablation-and-analysis-of-related-factors-100569361","NCT06693245","Observation of Pain During the Treatment of Great Saphenous Vein Using Microwave Ablation， and Analysis of Related Factors","Inclusion Criteria:\n\n1. Age≥ 18 years old, ≤ 90 years old;\n2. the patient's life expectancy is greater than 12 months;\n3. The clinical diagnosis is primary VVs, CEAP classification C2-C6, and the GSV segment needs to be treated, including pain, burning sensation, heaviness, fatigue, itchy skin, night cramps and other clinical symptoms;\n4. Doppler ultrasound confirmed that the diameter of GSV was greater than 3mm and less than 12mm when standing;\n5. Doppler ultrasound confirms that GSV is located in the saphenofascia or the distance between GSV and the skin surface is \\>1cm;\n6. endovenous microwave ablation treatment only for unilateral GSV walking area;\n7. The patient is willing to cooperate with the completion of the examination specified in the protocol.\n\nExclusion Criteria:\n\n1. GSV thrombosis, or combined with deep vein thrombosis, or previous history of deep vein thrombosis and pulmonary embolism;\n2. patients with recurrence after prior VVs-related surgery (C2r);\n3. the GSV trunk is severely distorted, and it is expected that the catheter will not be able to pass;\n4. Severe ischemia of the lower limbs, Ankle brachial pressure index (ABPI) \\\u003C 0.8;\n5. Known allergy to the drugs and device materials involved in the study;\n6. Previously implanted with a pacemaker or defibrillator, and currently receiving regular anticoagulation therapy (such as warfarin, heparin);\n7. Pregnant or lactating females;\n8. Patients who are unable or unwilling to participate in the study;\n9. Participating in the research of other drugs or devices;\n10. Skin malignancies other than non-melanoma that are being treated;\n11. daily use of narcotic drugs or non-steroidal anti-inflammatory drugs to control pain caused by venous disease;\n12. The investigator judged that endovenous treatment was not suitable;",{"count":196,"type":21},155,"1 Day","OBSERVATIONAL","Objective: This study is a single-center prospective observational research that recorded patients' pain scores at four time points during surgery (puncture and catheter insertion, swelling fluid injection, microwave generator operation, and end of surgery). It analyzed the correlation between pain during microwave ablation treatment for great saphenous vein varicosities and factors such as age, gender, body mass index, volume of swelling fluid used, and others, in order to summarize and improve surgical details to reduce patients' intraoperative pain.",[131,29,130],[202,203,204,205],"Varicose veins of the lower extremities","Endovenous Microwave Ablation","intraoperative pain","visual analogue scale of pain","2024-11-15",{"date":208,"type":46},"2024-11-18",{"date":185,"type":21},{"date":187,"type":21},{"name":144,"class":53}]